



IN THE DISTRICT COURT OF CLEVELAND COUNTY
STATE OF OKLAHOMA

Document split into multiple parts

STATE OF OKLAHOMA, ex rel.,)
MIKE HUNTER,)
ATTORNEY GENERAL OF OKLAHOMA,)

Plaintiff,)

vs.)

PART K

**Case No. CJ-2017-816
Judge Thad Balkman**

- (1) PURDUE PHARMA L.P.;)
- (2) PURDUE PHARMA, INC.;)
- (3) THE PURDUE FREDERICK COMPANY;)
- (4) TEVA PHARMACEUTICALS USA, INC.;)
- (5) CEPHALON, INC.;)
- (6) JOHNSON & JOHNSON;)
- (7) JANSSEN PHARMACEUTICALS, INC;)
- (8) ORTHO-MCNEIL-JANSSEN)
PHARMACEUTICALS, INC., n/k/a)
JANSSEN PHARMACEUTICALS;)
- (9) JANSSEN PHARMACEUTICA, INC.,)
n/k/a JANSSEN PHARMACEUTICALS, INC.;)
- (10) ALLERGAN, PLC, f/k/a ACTAVIS PLC,)
f/k/a ACTAVIS, INC., f/k/a WATSON)
PHARMACEUTICALS, INC.;)
- (11) WATSON LABORATORIES, INC.;)
- (12) ACTAVIS LLC; and)
- (13) ACTAVIS PHARMA, INC.,)
f/k/a WATSON PHARMA, INC.,)

Defendants.)

STATE OF OKLAHOMA } S.S.
CLEVELAND COUNTY }

FILED

MAY 23 2019

In the office of the
Court Clerk MARILYN WILLIAMS

PRETRIAL CONFERENCE ORDER

Exhibit No.	Rates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
18888	Publicly Available	Patricia M. Danzon, "Pharmacy Benefit Management: Are Reporting Requirements Pro- or Anticompetitive?" <i>International Journal of the Economics of Business</i> 22, no. 2, pp. 245-261	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18889	Publicly Available	Peter J. Neumann, "Evidence-Based and Value-Based Formulary Guidelines," <i>Health Affairs</i> 23, no. 1, pp. 124-34	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18890	Publicly Available	Peter R. Darke and Robin J.B. Ritchie, "The Defensive Consumer: Advertising Deception, Defensive Processing, and Distrust," <i>Journal of Marketing Research</i> 44, no. 1, pp. 114-127	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18891	Publicly Available	Pierre Azoulay, "Do Pharmaceutical Sales Respond to Scientific Evidence?" <i>Journal of Economics & Management Strategy</i> 11, no. 4, pp. 551-594	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18892	Publicly Available	Pradep K. Chintagunta et al., "Information, Learning, and Drug Diffusion: The Case of Cox-2 Inhibitors," <i>Quantitative Marketing and Economics</i> 7, no. 4, pp. 399-433	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18893	Publicly Available	Pradij K. Mohuri et al., "Associations of Nonmedical Pain Reliever Use and Initiation of Heroin Use in the United States," <i>CBHSQ Data Review</i>	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18894	Publicly Available	Robert P. Navarro et al., "Chapter 11: Prescription Drug Benefits in Managed Care," in <i>Essentials of Managed Health Care</i> , Sixth Edition, ed. Peter R. Kongstvedt (Burlington, MA: Jones & Bartlett Learning)	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18895	Publicly Available	Roger Chou and Elizabeth Clark, "Drug Class Review on Long-Acting Opioid Analgesics for Chronic Non-Cancer Pain," Oregon Evidence-based Practice Center	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18896	Publicly Available	Sam Peltzman, "The Effects of FTC Advertising Regulation," <i>The Journal of Law and Economics</i> 24, no. 3, pp. 403-448	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Pages No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
18897	Publicly Available	Sharmim Radakrishnan, "The Impact of Information in Health Care Markets: Prescription Drug Monitoring Programs and Abuse of Opioid Pain Relievers," Working Paper	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18898	Publicly Available	Sheila Smith et al., "Income, Insurance, And Technology: Why Does Health Spending Outpace Economic Growth?" <i>Health Affairs</i> 28, no. 5, pp. 1276-1284	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18899	Publicly Available	Shellee L. Keast et al., "Strategies Aimed at Controlling Misuse and Abuse of Opioid Prescription Medications in a State Medicaid Program: A Policymaker's Perspective," <i>The American Journal of Alcohol and Drug Abuse</i> 41, no. 1, pp. 1-6	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18900	Publicly Available	Sridhar Narayanan et al., "Temporal Differences in the Role of Marketing Communication in New Product Categories," <i>Journal of Marketing Research</i> 42, no. 3, pp. 278-290	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18901	Publicly Available	Stacie B. Dusezina et al., "Impact of FDA Drug Risk Communications on Health Care Utilization and Health Behaviors: A Systematic Review," NIH Public Access Author Manuscript	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18902	Publicly Available	Stephen W. Patrick et al., "Implementation of Prescription Drug Monitoring Programs Associated with Reductions in Opioid-Related Death Rates," <i>Health Affairs</i> 35, no. 7, pp. 1324-1332	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18903	Publicly Available	Steven Raphael and Rudolf Winter-Ebmer, "Identifying the Effect of Unemployment on Crime," <i>The Journal of Law and Economics</i> 44, no. 1, pp. 259-283	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18904	Publicly Available	Susan Athey and Guido W. Imbens, "The State of Applied Econometrics: Causality and Policy Evaluation," <i>Journal of Economic Perspectives</i> 31, no. 2, pp. 3-32	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18905	Publicly Available	Tatyana Lyapustina et al., "Effect of a 'Pill Mill' Law on Opioid Prescribing and Utilization: The Case of Texas," <i>Drug and Alcohol Dependence</i> 159, pp. 190-197	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	Sare's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
18906	Publicly Available	Theodore J. Cicero et al., "Multiple Determinants of Specific Modes of Prescription Opioid Diversion," <i>Journal of Drug Issues</i> 41, no. 2, pp. 283-304	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18907	Publicly Available	Theodore Stanley, "The Fentanyl Story," <i>The Journal of Pain</i> 15, no. 12, pp. 1215-1226	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18908	Publicly Available	Thomas C. Buchmuller and Colleen Carey, "The Effect of Prescription Drug Monitoring Programs on Opioid Utilization in Medicare," NBER Working Paper No.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18909	Publicly Available	Trisha Greenhalgh et al., "Making Decisions about Benefits and Harms of Medicines," <i>BMJ</i> 329, pp. 47-50	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18910	Publicly Available	Victoria Divino et al., "Assessing the Impact of Extended Release/Long Acting Opioid Analgesics Risk Evaluation and Mitigation Strategies on Opioid Prescription Volume," <i>Journal of Opioid Management</i> 13, no. 3	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18911	Publicly Available	W. A. V. Clark and Karen L. Avery, "The Effects of Data Aggregation in Statistical Analysis," <i>Geographical Analysis</i> 8, pp. 428-439	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18912	Publicly Available	W. S. Robinson, "Ecological Correlations and the Behavior of Individuals," <i>American Sociological Review</i> 15, no. 3, pp. 351-357	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18913	Publicly Available	Walter Smalley et al., "Contraindicated Use of Cisapride: Impact of Food and Drug Administration Regulatory Action," <i>JAMA</i> 284, no. 23, pp. 3036-3039	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18914	Publicly Available	William N. Evans et al., "How the Reformulation of Oxycodone Ignited the Heroin Epidemic," <i>The Review of Economics and Statistics</i> 101, no. 1, pp. 1-15	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
18915	Publicly Available	Y. Richard Wang and Mark V. Pauly, "Spillover Effects of Restrictive Drug Formularies on Physician Prescribing Behavior: Evidence from Medicaid," <i>Journal of Economics & Management Strategy</i> , 14, no. 3, pp. 755-773	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18916	Publicly Available	Yuhua Bao et al., "Prescription Drug Monitoring Programs Are Associated with Sustained Reductions in Opioid Prescribing by Physicians," <i>Health Affairs</i> 35, no. 6, pp. 1045-1051	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18917	Publicly Available	Zhiqiao Wang et al., "Cost-Effectiveness Analysis and the Formulary Decision-Making Process," <i>Journal of Managed Care Pharmacy</i> , 10, no. 1, pp. 48-59	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18918	Publicly Available	"2017 Employer Health Benefits Survey, Section 9: Prescription Drug Benefits," <i>Kaiser Family Foundation</i> , https://www.kff.org/report-section/elhs-2017-section-9-prescription-drug-benefits	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18919	Publicly Available	"5 Best Practices for P&T Committee Members," <i>UW-Madison School of Pharmacy, Division of Pharmacy Professional Development</i> , https://ce.pharmacy.wisc.edu/blog/5-best-practices-for-pt-committee-members	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18920	Publicly Available	"About AMCP," <i>AMCP</i> , http://www.amcp.org/AboutUs.aspx?id=8821	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18921	Publicly Available	Andrew Joseph, "CVS Tightens Restrictions on Opioid Prescriptions in Bid to Stanch Epidemic," <i>Statnews</i> , https://www.statnews.com/2017/09/21/cvs-opioid-prescription-limits	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18922	Publicly Available	"Approved Risk Evaluation and Mitigation Strategies (REMS)," <i>FDA</i> , https://www.accessdata.fda.gov/scripts/cder/remis/ , accessed February 16, 2019	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them.)
18923	Publicly Available	"Approved Risk Evaluation and Mitigation Strategies (REMS)—AndroGel 1% (testosterone)," <i>FDA</i> , https://www.accessdata.fda.gov/scripts/cder/remis/index.cfm?event=RemsDetails.page&R EMS=4	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18924	Publicly Available	"Approved Risk Evaluation and Mitigation Strategies (REMS)—Opioid Analgesic REMS," <i>FDA</i> , https://www.accessdata.fda.gov/scripts/cder/remis/index.cfm?event=RemsDetails.page&R EMS=17	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18925	Publicly Available	"Approved Risk Evaluation and Mitigation Strategies (REMS)—Transmucosal Immediate-Release Fentanyl (TIRF) Products," <i>FDA</i> , https://www.accessdata.fda.gov/scripts/cder/remis/index.cfm?event=RemsDetails.page&R EMS=17	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18926	Publicly Available	"Balancing Access and Use of Opioid Therapy," AMCP Foundation Meeting Report, http://www.amcp.org/FdnSymp_2016Report/	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18927	Publicly Available	"Bart Launches Generic Actiq Cancer Pain Management Product," <i>FDAnews</i> , https://www.fdanews.com/articles/62893-bart-launches-generic-actiq-cancer-pain-management-product	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18928	Publicly Available	Behavioral Health Coordinating Committee Prescription Drug Abuse Subcommittee, "Addressing Prescription Drug Abuse in the United States: Current Activities and Future Opportunities," U.S. Department of Health and Human Services Report	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18929	Publicly Available	"Buprenorphine," Substance Abuse and Mental Health Services Administration, https://www.samhsa.gov/medication-assisted-treatment/treatment/buprenorphine	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
18930	Publicly Available	"Buprenorphine Waiver Management," Substance Abuse and Mental Health Services Administration, https://www.samhsa.gov/medication-assisted-treatment/training-materials-resources/buprenorphine-waiver	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18931	Publicly Available	CBO Paper, "Technological Change and the Growth of Health Care Spending," <i>Congressional Budget Office</i> , https://www.cbo.gov/sites/default/files/110th-congress-2007-2008/reports/01-31-techhealth.pdf	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18932	Publicly Available	CBO Testimony, "Growth in Health Care Costs: Statement of Peter R. Orszag, Director, before the Committee on the Budget, United States Senate," <i>Congressional Budget Office</i> , https://www.cbo.gov/sites/default/files/110th-congress-2007-2008/reports/01-31-healthtestimony.pdf	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18933	Publicly Available	"CDC's Response to the Opioid Overdose Epidemic," CDC, https://www.cdc.gov/opioids/strategy.html	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18934	Publicly Available	CDER and CBER, "Guidance for Industry: Development and Use of Risk Minimization Action Plans," FDA Report	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18935	Publicly Available	Center for Behavioral Health Statistics and Quality, "How People Obtain the Prescription Pain Relievers they Misuse," SAMHSA Report	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18936	Publicly Available	Center for Evidence-Based Policy, "The Drug Effectiveness Review Project (DERP)," https://centerforevidencebasedpolicy.org/our	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18937	Publicly Available	"Central Nervous System/Behavioral Health," OCHA, http://www.okhca.org/providers.aspx?id=12090#34	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
18938	Publicly Available	Cole Werble, "Health Policy Brief: Pharmacy Benefit Managers," <i>Health Affairs</i> , https://www.healthaffairs.org/doi/10.1377/hltp.620171409.000178/full/	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18939	Publicly Available	"CVS Caremark Opioid Quantity Limits Pharmacy Reference Guide," <i>CVS Caremark</i> , https://www.caremark.com/portal/asset/Opioid-Reference-Guide.pdf	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18940	Publicly Available	Dave Chase, "The Opioid Crisis is Partly Fueled by Insurers' and Employers' Approach to Back Pain," <i>STAT</i> , https://www.statnews.com/2019/03/27/opioid-crisis-insurers-employers-back-pain	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18941	Publicly Available	DEA, "Controlled Substances Listed in Schedule II," https://www.deadiversion.usdoj.gov/21cfr/cf/1306/1306_11.htm	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18942	Publicly Available	DEA, "Diversion Control Division," https://www.dea.gov/diversion-control-division	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18943	Publicly Available	DEA, "Drug Scheduling," https://www.dea.gov/drug-scheduling	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18944	Publicly Available	DEA, "Home," https://www.dea.gov/	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18945	Publicly Available	DEA, "Mission," https://www.dea.gov/mission	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18946	Publicly Available	DEA, "Section IX – Valid Prescription Requirements," https://www.deadiversion.usdoj.gov/pubs/mannuals/pharm2/pharm_content.htm	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18947	Publicly Available	DEA, "Section V – Valid Prescription Requirements," https://www.deadiversion.usdoj.gov/pubs/mannuals/pract/sections.htm	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Tera exhibit because J&J and Janssen have not had the opportunity to review them)
18948	Publicly Available	DEA, "Subchapter I – Control and Enforcement: Part B – Authority to Control Standards and Schedules," https://www.deadiversion.usdoj.gov/21cfr/21usc/812.htm	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18949	Publicly Available	Deb Ramsey, "DEA Reduces 2017 Opioid Production Quotas – Mostly by Eliminating 'Buffer,'" <i>PT in Motion News</i> , http://www.apta.org/PTinMotion/News/2016/10/11/DEAOpioidQuotas/	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18950	Publicly Available	"Definitions of Health Insurance Terms," <i>Bureau of Labor Services</i> , https://www.bls.gov/nsc/ebs/sp/healthterms.pdf	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18951	Publicly Available	"Development & Approval Process (Drugs)," <i>FDA</i> , https://www.fda.gov/Drugs/Development/ApprovalProcess/default.htm	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18952	Publicly Available	DOJ Press Release, "Justice Department DEA Propose Significant Opioid Manufacturing Reduction in 2019," https://www.justice.gov/opa/pr/justice-department-dea-propose-significant-opioid-manufacturing-reduction-2019	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18953	Publicly Available	"Drug Effectiveness Review Project (DERP)," <i>Pacific Northwest Evidence Based Practice Center</i> , https://www.ohsu.edu/xd/research/centers-institutes/evidence-based-practice-center/drug-effectiveness-review-project/index.cfm	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18954	Publicly Available	"Drug Formulary," <i>Molina Healthcare</i> , https://www.molinahealthcare.com/providers/R/medicaid/drug/pages/formulary.aspx	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18955	Publicly Available	"Drug Utilization Review (DUR) Board," <i>Ohio Department of Medicaid</i> , https://pharmacy.medicaid.ohio.gov/drug-utilization-review-board	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18956	Publicly Available	Drugs & Crime Data Center & Clearinghouse, "Fact Sheet: Drug-Related Crime," U.S. Department of Justice Report No. NCI-149286	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
18957	Publicly Available	"Drugs@FDA: FDA Approved Drug Products," <i>FDA</i> , https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021015	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402, Speculative, Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18958	Publicly Available	Executive Office of the President of the United States, "Oklahoma Drug Control Update," https://obamawhitehouse.archives.gov/sites/default/files/docs/state_profile_-_oklahoma_0.pdf	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402, Speculative, Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18959	Publicly Available	"Extended-Release (ER) and Long-Acting (LA) Opioid Analgesics Risk Evaluation and Mitigation Strategy (REMS)," FDA REMS, Paperwork Reference ID 3784602, https://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM311290.pdf	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402, Speculative, Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18960	Publicly Available	"FDA Education Blueprint for Health Care Providers Involved in the Treatment and Monitoring of Patients with Pain," <i>FDA</i> , https://www.accessdata.fda.gov/drugsatfda_docs/remms/Opioid_analgesic_2018_09_18_FDA_Blueprint.pdf	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402, Speculative, Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18961	Publicly Available	FDA, "Generic Drug Facts," https://www.fda.gov/drugs/resourcesforyou/consumers/buyingusingmedicinesafely/generichugs/ucm167991.htm	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402, Speculative, Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18962	Publicly Available	FDA, "New Drug Application (NDA)," https://www.fda.gov/drugs/types-applications/new-drug-application-nda	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402, Speculative, Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18963	Publicly Available	"FDA Ok's Narcotic Lollipop," <i>CBS News</i> , https://www.cbsnews.com/news/fda-oks-narcotic-lollipop/	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402, Speculative, Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18964	Publicly Available	FDA Press Release, "Statement from FDA Commissioner Scott Gottlieb, M.D., on Agency's Approval of Daxuvia and the FDA's Future Consideration of New Opioids," https://www.fda.gov/NewsEvents/Newsroc	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402, Speculative, Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
18965	Publicly Available	FDA Press Release, "Statement from FDA Commissioner Scott Gottlieb, M.D., on FDA's Continued, Careful Oversight of the REMS Associated with Transmucosal Immediate-Release Fentanyl Products." https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm615411.htm	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18966	Publicly Available	FDA Press Release, "Statement from FDA Commissioner Scott Gottlieb, M.D. on the Agency's 2019 Policy and Regulatory Agenda for Continued Action to Forcefully Address the Tragic Epidemic of Opioid Abuse." https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm632067.htm	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18967	Publicly Available	FDA, "Verify Wholesale Drug Distributor Licenses." https://www.fda.gov/Drugs/DrugSafety/DrugIntegrityandSupplyChainSecurity/ucm281446.htm	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18968	Publicly Available	FDA, "What Is the Approval Process for Generic Drugs?" https://www.fda.gov/Drugs/ResourceForYou/Consumers/BuyingUsingMedicineSafely/Generics/ucm506040.htm	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18969	Publicly Available	"FDA Withdraws Approval of ADHD Drug." NBC News, http://www.nbcnews.com/id/9806626/ns/health-mental-health/v/fda-withdraws-approval-adhd-drug/	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18970	Publicly Available	Federal Register, "Drug Enforcement Administration." https://www.federalregister.gov/agencies/drug-enforcement-administration	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18971	Publicly Available	Federal Register, "Food and Drug Administration." https://www.federalregister.gov/agencies/food-and-drug-administration	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18972	Publicly Available	Federal Register, "Regulations Implementing the Comprehensive Drug Abuse Prevention and Control Act of 1970," 36(80), pp. 7731-7826	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
18973	Publicly Available	"Formulary Development and Management at CVS Caremark," <i>CVS Caremark Access Manual</i> , https://www.tirfremisaccess.com/TirfUI/remis/pdf/faq.pdf	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18974	Publicly Available	"Frequently Asked Questions," <i>TIRF REMS Access Manual</i> , https://www.tirfremisaccess.com/TirfUI/remis/pdf/faq.pdf	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18975	Publicly Available	"Good Samaritan Overdose Prevention Laws," <i>PDAPS</i> , http://pdaps.org/datasets/good-samaritan-overdose-laws-1501695153	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18976	Publicly Available	"Health Insurance Plans May Be Fueling Opioid Epidemic," <i>Johns Hopkins Bloomberg School of Public Health</i> , https://www.jhsph.edu/news/news-releases/2018/health-insurance-plans-may-be-fueling-opioid-epidemic.html	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18977	Publicly Available	"History of Prescription Drug Monitoring Programs," Prescription Drug Monitoring Program and Training and Technical Assistance Center Technical Assistance Guide, https://www.pdmassist.org/pdf/PDMP_admm/TAG_History_PDMPs_final_20180314.pdf	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18978	Publicly Available	"How Do Medicare Advantage Plans Work?" <i>Medicare.gov</i> , https://www.medicare.gov/sign-up-change-plans/types-of-medicare-health-plans/medicare-advantage-plans/how-do-medicare-advantage-plans-work	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18979	Publicly Available	"How is Medicare Funded?" <i>Medicare.gov</i> , https://www.medicare.gov/about-us/how-is-medicare-funded	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18980	Publicly Available	"How to Get Drug Coverage," <i>Medicare.gov</i> , https://www.medicare.gov/drug-coverage-part-d/how-to-get-drug-coverage	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
18981	Publicly Available	ICE Benchmark Administration Limited (IBA), "Gold Fixing Price 3:00 P.M. (London time) in London Bullion Market, based in U.S. Dollars [GOLDPMGBD228NLBM], FRED, Federal Reserve Bank of St. Louis, https://fred.stlouisfed.org/series/GOLDPMGBD228NLBM	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18982	Publicly Available	Jeanie Lertche Davis, "Baycol Removed from Market," <i>WebMD</i> , https://www.webmd.com/cholesterol-management/news/20050322/baycol-removed-from-market	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18983	Publicly Available	Jennifer Gershman, "4 Controlled Substance Laws and Regulations You Should Know," <i>Pharmacy Times</i> , https://www.pharmacytimes.com/contributor/jennifer-gershman-pharmd-cph/2017/07/4-controlled-substance-laws-and-regulations-you-should-know	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18984	Publicly Available	Joe Davidson, "Is DEA a Bad Guy in Opioid Addiction Fight?" <i>The Washington Post</i> , https://www.washingtonpost.com/news/gow-erpost/wp/2016/06/23/is-dea-a-bad-guy-in-opioid-addiction-fight/?hpid=hp_hp-top-table-main-opioid-addiction-1%3Ahomepage%3Fh=opio&hpid=hp_hp-top-table-main-opioid-addiction-1%3Ahomepage%3Fh=opio	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18985	Publicly Available	John Temple, "DEA Secretly OKs Killer Quantities of Oxy and Morphine," <i>The Daily Beast</i> , https://www.thedailybeast.com/dea-secretly-oks-killer-quantities-of-oxy-and-morphine	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18986	Publicly Available	Jonathan D. Rockoff and Ron Winslow, "New Medicines Emerge, but Few Blockbusters: Drug Makers Find It Hard to Elbow Aside Established, Often Cheaper, Products," <i>The Wall Street Journal</i> , https://www.wsj.com/articles/new-medicines-emerge-but-few-blockbusters-1387155660?mod=searchresults&page=1&pos=3&testla="	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
18987	Publicly Available	Kara Subyak, "Doctor Accused of Running Pill Mill," https://fox8.com/2013/12/19/doctor-accused-of-running-pill-mill/	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
18988	Publicly Available	Kate Thomas and Charles Ornstein, "Amid Opioid Crisis, Insurers Restrict Prices, Less Addictive Painkillers," <i>The New York Times</i> , https://www.nytimes.com/2017/09/17/health/opioid-painkillers-insurance-	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18989	Publicly Available	"Key Substance Use and Mental Health Indicators in the United States: Results from the 2017 National Survey on Drug Use and Health." Substance Abuse and Mental Health Services Administration, U.S. Department of Health and Human Services Publication No. SMA 18-5068	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18990	Publicly Available	KFF, "Medicare Prescription Drug Plans: Number of Medicare Beneficiaries with Creditable Prescription Drug Coverage, by Type," https://www.kff.org/medicare/state-indicator/medicare-rx-drug-coverage/?currentTimestframe=0&sortModel=%7B%22colId%22:%22location%22,%22sort%22:%22asc%22%7D	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18991	Publicly Available	Lee H. Roschush and Marc N. Wagner, "The DEA Quota System," https://www.fdi.org/2018/08/update-the-dea-quota-system/	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18992	Publicly Available	"List of Extended-Release and Long-Acting Opioid Products Required to Have an Opioid REMS," <i>FDA</i> , https://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm251735.htm	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18993	Publicly Available	"Model Policy for the Use of Controlled Substances for the Treatment of Pain," Federation of State Medical Boards of the United States, Inc. Report, https://www.fhs.gov/painmanagement/includes/themes/newstheme/display_objects/documents/modelpolicytreatmentpain.pdf	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
18994	Publicly Available	"Naloxone Overdose Prevention Laws," <i>PDAPS</i> , http://pdaps.org/datasets/laws-regulating-administration-of-naloxone-1501695139	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18995	Publicly Available	National Center for Injury Prevention and Control, "Patient Review & Restriction Programs," CDC Expert Panel Meeting Report	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18996	Publicly Available	National Conference of Insurance Legislators, "Best Practices to Address Opioid Abuse, Misuse & Diversion," http://aahpm.org/uploads/advocacy/07192014NCOILOpioidBestPracticesEXPANDED-1.pdf	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18997	Publicly Available	"National Drug Threat Assessment 2011," U.S. Department of Justice National Drug Intelligence Center Product No. 2011-Q0317-001	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18998	Publicly Available	"Number of DATA-Waived Practitioners Newly Certified per Year," Substance Abuse and Mental Health Services Administration, https://www.samhsa.gov/medication-assisted-treatment/physician-program-data/certified-physicians?field_bup_us_state_code_value=OH , accessed May 2, 2019	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18999	Publicly Available	Office of Inspector General, "FDA's Review Process for New Drug Applications: A Management Review," Department of Health and Human Services Report	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
19000	Publicly Available	"Opioid Analgesic Risk Evaluation and Mitigation Strategy (REMS)," <i>FDA</i> , https://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm163647.htm	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
19001	Publicly Available	"Opioid Overdose Reversal with Naloxone (Narcan, Evzio)," <i>National Institute on Drug Abuse</i> , https://www.drugabuse.gov/related-topics/opioid-overdose-reversal-naloxone-narcan-evzio	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
19002	Publicly Available	"Oxycontin: Balancing Risks and Benefits," Senate Hearing of the Committee on Health Education, Labor, and Pensions, No. 107-287, https://www.gpo.gov/fdsys/pkg/CHRG-107shrg77770/html/CHRG-107shrg77770.htm	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.
19003	Publicly Available	Paul B. Ginsburg, "High and Rising Health Care Costs: Demystifying U.S. Health Care Spending," <i>The Synthesis Project, Robert Wood Johnson Foundation, Research Synthesis Report No. 16</i> , https://folio.inpubi.edu/bitstream/handle/10244/634/101508.policy.synthesis.costdrivers.rpt.pdf?sequence=2	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.
19004	Publicly Available	Paul Tough, "The Alchemy of OxyContin," <i>The New York Times Magazine</i> , https://www.nytimes.com/2001/07/29/magazine/the-alchemy-of-oxycontin.htm	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.
19005	Publicly Available	PDMP TTAC, "Mandatory PDMP Enrollment," http://www.pdmpassist.org/pdf/Mandatory_Enrollment_Conditions_20181120.pdf	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.
19006	Publicly Available	PDMP TTAC, "Mandatory PDMP Use," http://www.pdmpassist.org/pdf/Mandatory_Query_Conditions_20181120.pdf	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.
19007	Publicly Available	"Pharmacy," <i>CareSource</i> , https://www.caresource.com/oh/providers/education/patient-care/pharmacy/medicaid/	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.
19008	Publicly Available	"Pharmacy," <i>UnitedHealthcare</i> , https://www.uhc.com/employer/pharmacy	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.
19009	Publicly Available	Pia Malbran, "What's a Pill Mill?" <i>CBS News</i> , https://www.cbsnews.com/news/whats-a-pill-mill/	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.
19010	Publicly Available	"Prescription Drug Monitoring Programs: Evidence-Based Practices to Optimize Prescriber Use," The Pew Charitable Trusts Report	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
19011	Publicly Available	"Prescription Opioids and Heroin," <i>National Institute on Drug Abuse</i> . https://www.drugabuse.gov/publications/research-reports/relationship-between-prescription-drug-abuse-heroin-use/introduction	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.
19012	Publicly Available	"Prescription," <i>Paramount HealthCare</i> . https://www.paramounthealthcare.com/services/brokers/plans-and-services/prescription	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.
19013	Publicly Available	"Preventing the Consequences of Opioid Overdose: Understanding Naloxone Access Laws," Substance Abuse and Mental Health Services Administration, https://www.samhsa.gov/capt/sites/default/files/resources/naloxone-access-laws-tool-pdfs	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.
19014	Publicly Available	"Prior Authorization and the Formulary Exception Process," <i>AMCP</i> . http://www.amcp.org/WorkArea/DownloadAsset.aspx?id=9795	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.
19015	Publicly Available	"Quantity Limits — Core and Select," <i>OptumRx</i> . http://doa.alaska.gov/arb/benefits/materials/AlaskaCarePharmacy_QuantityLimits.pdf	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.
19016	Publicly Available	"Quantity Limits," <i>Medicare.gov</i> . https://www.medicare.gov/node/39146	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.
19017	Publicly Available	"Risk Evaluation and Mitigation Strategies (REMS)," <i>FDA</i> . https://www.fda.gov/Drugs/DrugSafety/REMS/default.htm	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.
19018	Publicly Available	"Roles of Different Participants in REMS," <i>FDA</i> . https://www.fda.gov/Drugs/DrugSafety/REMS/ucm592662.htm	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.
19019	Publicly Available	"Schedules of Controlled Substances," <i>Federal Register</i> 36, no. 80, pp. 7802–7812	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
19020	Publicly Available	"States Reporting Managed Care Pharmacy Uniform Preferred Drug List (PDL) Requirements," <i>KFF</i> , https://www.kff.org/medical/state-indicator/states-reporting-managed-care-pharmacy-uniform-preferred-drug-list-pdl-requirements/?currentTimeframe=0&sortMethod=-%7B%22collId%22:%22Location%22,%22sort%22:%22asc%22%7D	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.
19021	Publicly Available	Steve Edelson, "Faster Followers in Pain," <i>Biocentury</i> , https://www.biocentury.com/biocentury/product-development/2007-08-13/faster-followers-pain?kw=Fentora%3C%7C%3Efenany%20effective%20buccal%20table	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.
19022	Publicly Available	"Study of Pharmaceutical Benefit Management," Pricewaterhouse Coopers HCPA Contract No. 500-97-0399/0097	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.
19023	Publicly Available	"The AMCP Format for Formulary Submissions, Version 4.0: A Format for Submission of Clinical and Economic Evidence in Support of Formulary Consideration," Academy of Managed Care Pharmacy, http://www.amcp.org/FormatV4 .	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.
19024	Publicly Available	"Timeline of Selected FDA Activities and Significant Events Addressing Opioid Misuse and Abuse," <i>FDA</i> , https://www.fda.gov/downloads/Drugs/DrugSafety/InformationbyDrugClass/UCM566985.pdf	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.
19025	Publicly Available	"Transmucosal Immediate Release Fentanyl (TIRF) Products Risk Evaluation and Mitigation Strategy (REMS): Education Program for Prescribers and Pharmacists," <i>TIRF REMS Access Manual</i> , https://www.tirfremssaccess.com/TIRFItems/pdf/education-and-ka.pdf	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Tera exhibit because J&J and Janssen have not had the opportunity to review them)
19026	Publicly Available	"Understanding Unapproved Use of Approved Drugs 'Off Label.'" <i>U.S. Food & Drug Administration</i> , https://www.fda.gov/patients/learn-about-expanded-access-and-other-treatment-options/understanding-unapproved-use-approved-drugs-label	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.
19027	Publicly Available	"Vital Signs: Overdoses of Prescription Opioid Pain Relievers—United States, 1999–2008." <i>CDC Morbidity and Mortality Weekly Report</i> 60, no. 43. https://www.cdc.gov/mmwr/preview/mmwrhtml/mm6043a4.htm?cid=mm6043a4_w	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.
19028	Publicly Available	"What is Prior Authorization and How Does the Process Work?" <i>Cigna</i> , https://www.cigna.com/individuals-families/understanding-insurance/what-is-prior-authorization	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.
19029	Publicly Available	"What Marketplace Health Insurance Plans Cover." <i>HealthCare.gov</i> , https://www.healthcare.gov/coverage/what-marketplace-plans-cover/	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.
19030	Publicly Available	"What States Need to Know about PDMs." CDC, https://www.cdc.gov/drugoverdose/pdmp/states.html	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.
19031	Publicly Available	"What's in a REMS?" FDA, https://www.fda.gov/Drugs/DrugSafety/REMS/ucm392636.htm	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.
19032	Publicly Available	"WHO Model List of Essential Medicines." World Health Organization Report, 20 th List https://apps.who.int/iris/bitstream/handle/10665/273826/EML-20-eng.pdf	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.
19033	Publicly Available	Anuj Shah et al. (2017) table, "One- and 3-year probabilities of continued use, and median time to discontinuation of opioid use, by choice of first opioid prescription"	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.
19034	Publicly Available	Erin Cavanaugh et al. (2011) chart, "Sales of Rx gastrointestinal drugs during time period included in study, 1991–2006"	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
19035	Publicly Available	FDA, "Transmucosal Immediate Release Fentanyl (TIRF) Risk Evaluation and Mitigation Strategy (REMS)," Reference ID no. 3677583	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.
19036	Publicly Available	Jonathan D. Rockoff and Ron Winslow (2013) chart, "Off to a Slower Start: New drug launches in the U.S. in recent years haven't been as successful as they had been"	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.
19037	Publicly Available	"How the opioid crackdown is backfiring," 2018. https://www.politico.com/story/2018/08/28/how-the-opioid-crackdown-is-backfiring-752183	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.
19038	Publicly Available	"Hydralazine ER Label, September 2018," 2018. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/2006627s007s0081b1.pdf	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
19039	Publicly Available	"Neurontin (Gabapentin) Label," 2017. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020235s064_020882s047_021129s046b1.pdf	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
19040	Publicly Available	"Tazodone Label," 2015. https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/071196s062b1.pdf	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
19041	Publicly Available	Abernethy, Amy P., Jane L. Wheeler, and Barry V. Fortner. "A health economic model of breakthrough pain." <i>American Journal of Managed Care</i> Vol. 14, No. 5 Supplement 1 (2008), pp. S129-40.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
19042	Publicly Available	American Addiction Centers, "Drug Abuse and Chemical Imbalance in the Brain: Dopamine, Serotonin & More," https://americanaddictioncenters.org/health-complications-addiction/chemical-imbalance/	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
19043	Publicly Available	American Chronic Pain Association, "ACPA Resource Guide to Chronic Pain Management: An Integrated Guide to Medical, Interventional, Behavioral, Pharmacologic and Rehabilitation Therapies," 2018. https://www.theacpa.org/wp-content/uploads/2018/03/ACPA_Resource	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
19044	Publicly Available	American Pain Foundation, "Treatment Options: A Guide for People Living with Pain."	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
19045	Publicly Available	American Psychiatric Association, "Opioid Use Disorder." Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V), 304.00, 2013.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
19046	Publicly Available	American RSDHope, "Medical Articles - Your Doctor and You." http://www.rsdhope.org/your-doctor-and-you.html	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
19047	Publicly Available	American Society of Addiction Medicine, "Definition of Addiction," 2011, available at https://www.asam.org/resources/definition-of-addiction	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
19048	Publicly Available	Ashburn, Michael A. et al. "The efficacy and safety of fentanyl/buccal tablet compared with immediate-release oxycodone for the management of breakthrough pain in opioid-tolerant patients with chronic pain." <i>Anesthesia & Analgesia</i> Vol. 112, No. 3 (2011): pp. 693-702.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
19049	Publicly Available	Ballantyne, Jane C. "Opioids for the treatment of chronic pain: mistakes made, lessons learned, and future directions." <i>Anesthesia & Analgesia</i> Vol. 125, No. 5 (2017): pp. 1769-78.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
19050	Publicly Available	Berritini, Wade. "A brief review of the genetics and pharmacogenetics of opioid use disorders." <i>Dialogues in Clinical Neuroscience</i> Vol. 19, No. 3 (2017): pp. 229-36. https://www.ncbi.nlm.nih.gov/pubmed/29302220	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
19051	Publicly Available	Bishop, Darla et al. <i>Pregnant Women and Substance Use: Overview of Research & Policy in the United States: The George Washington University's Jacobs Institute of Women's Health</i> (February 2017). Available at https://hsr.c.himmelfarb.gwu.edu/sphhs_centers_jacobs/5/	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
19052	Publicly Available	Caraceni, Augusto, et al. "Guidelines for the management of breakthrough pain in patients with cancer." Journal of the National Comprehensive Cancer Network Vol. 11, Supplement 1(2013); pp. S-29-S-30.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
19053	Publicly Available	"CDC Advises Against Misapplication of the Guideline for Prescribing Opioids for Chronic Pain," 2019. https://www.cdc.gov/media/releases/2019/s0424-advises-misapplication-guideline-prescribing-opioids.html	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
19054	Publicly Available	Centers for Disease Control and Prevention, "Fact Sheets - Alcohol Use and Your Health," https://www.cdc.gov/alcohol/fact-sheets/alcohol-use.htm	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
19055	Publicly Available	Centers for Disease Control and Prevention, "Fentanyl," https://www.cdc.gov/drugoverdose/opioids/fentanyl.html	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
19056	Publicly Available	Cephalon, Inc., Form 10-K-405, filed March 30, 2001.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
19057	Publicly Available	Chang, Andrew, et al. "Transmucosal immediate-release fentanyl for breakthrough cancer pain: opportunities and challenges for use in palliative care." Journal of Pain & Palliative Care Pharmacotherapy Vol. 29, No. 3 (2015); pp. 247-60.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
19058	Publicly Available	Cheadle, Martin D., et al. "Prevalence of suicidal ideation in patients with chronic non-cancer pain referred to a behaviorally based pain program." Pain Physician Vol. 17, No. 3 (2014); pp. E339-67.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
19059	Publicly Available	Chou, Roger, et al. "Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain." The Journal of Pain Vol. 10, No. 2 (2009); pp. 113-30. e22.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Tera exhibit because J&J and Janssen have not had the opportunity to review them)
19060	Publicly Available	Coluzzi, Paul H., et al. "Breakthrough cancer pain: a randomized trial comparing oral transmucosal fentanyl citrate (OTFC®) and morphine sulfate immediate release (MSIR®)." <i>Pain Vol. 91, No. 1-2</i> (2001): pp. 123-30.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
19061	Publicly Available	Dowell, Deborah, Tamara Haegerich, and Roger Chou. "No Shortcuts to Safer Opioid Prescribing." <i>New England Journal of Medicine</i> (2019). Online at https://www.nejm.org/doi/full/10.1056/NEJMp1904190 .	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
19062	Publicly Available	Dowell, Deborah, Tamara Haegerich, and Roger Chou. "CDC Guideline for Prescribing Opioids for Chronic Pain — United States, 2016." <i>Morbidity and Mortality Weekly Report Vol. 65, No. 1</i>	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.
19063	Publicly Available	Dueñas, Maria, et al. "A review of chronic pain impact on patients, their social environment and the health care system." <i>Journal of Pain Research Vol. 9</i> (2016): pp. 457-61.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.
19064	Publicly Available	FDA. "Generic Drugs: Questions & Answer." https://www.fda.gov/Drugs/Resources/ForYou/Consumers/QuestionsAnswers/ucm100100.htm	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.
19065	Publicly Available	FDA. "A Guide to Safe Use of Pain Medicine." https://www.fda.gov/ForConsumers/ConsumerUpdates/ucm095673.htm	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.
19066	Publicly Available	FDA. "REMS: FDA's Application of Statutory Factors in Determining When a REMS Is Necessary, Guidance for Industry." April 2019. https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidance/UCN521504.pdf	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.
19067	Publicly Available	FDA. "Transmucosal Immediate Release Fentanyl (TIRF) Risk Evaluation and Mitigation Strategy (REMS)." August 2017. https://www.accessdata.fda.gov/drugsatfda_docs/ems/TIRF_2017-09-07_Full.pdf .	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
19068	Publicly Available	Federation of State Medical Boards, "Guidelines for the Chronic Use of Opioid Analgesics," April 2017. http://www.fsmb.org/sitesassets/advocacy/policies/opioid_guidelines_as_adopted_april-2017_final.pdf .	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.
19069	Publicly Available	Fine, Perry G., John Messina, Fang Xie, and James Rathnell, "Long-term safety and tolerability of fentanyl buccal tablet for the treatment of breakthrough pain in opioid-tolerant patients with chronic pain: an 18-month study." <i>Journal of Pain and Symptom Management</i> Vol. 40, No. 5 (2010): pp. 747-60.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
19070	Publicly Available	Fine, Perry G., Christine Miaskowski, and Michael Brennan, SELECT (Stratify, Examine, Listen, Evaluate, Control, Tailor): Opioid-Based Management of Persistent and Breakthrough Pain, 2008.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
19071	Publicly Available	Fishbain, David A., et al. "What percentage of chronic nonmalignant pain patients exposed to chronic opioid analgesic therapy develop abuse/addiction and/or aberrant drug-related behaviors? A structured evidence-based review." <i>Pain Medicine</i> Vol. 9, No. 4 (2008): pp. 444-59.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
19072	Publicly Available	Fishman, Scott M. <i>Responsible Opioid Prescribing: A Physician's Guide</i> . Washington, DC: Waterford Life Sciences, 2007.		
19073	Publicly Available	Forner, Barry V., Theodore A. Okon, and Russell K. Portnoy, "A survey of pain-related hospitalizations, emergency department visits, and physician office visits reported by cancer patients with and without history of breakthrough pain." <i>The Journal of Pain</i> Vol. 3, No. 1 (2002): pp. 38-44.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
19074	Publicly Available	Forner, Barry V., et al. "Description and Predictors of Direct and Indirect Costs of Pain Reported by Cancer Patients." <i>Journal of Pain and Symptom Management</i> , Vol. 25, No. 1 (2003): pp. 9-18.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
19075	Publicly Available	Frakt, Austin. "Overshadowed by the Opioid Crisis: A Comeback by Cocaine." The New York Times, March 5, 2018.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
19076	Publicly Available	Gaskin, Darrell J., and Patrick Richard. "The economic costs of pain in the United States." The Journal of Pain Vol. 13, No. 8 (2012): pp. 715-24.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
19077	Publicly Available	Goldberg, Daniel S., and Summer J. McGee. "Pain as a Global Public Health Priority." BMC Public Health Vol. 11, No. 1 (2011): pp. 770-75.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
19078	Publicly Available	Governor's Cabinet Opiate Action Team, "Ohio Guideline for the Management of Acute Pain Outside of Emergency Departments." 2016. https://mha.ohio.gov/Portals/0/assets/Initiatives/GCOAT/Guidelines-Acute-Pain-20160119.pdf	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.
19079	Publicly Available	Guarino, Anthony and Martha Cornell. "Breakthrough Pain in Non-Cancer Patients." Practical Pain Management Vol. 6, No. 3 (2012): pp. 1-5.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
19080	Publicly Available	Heubusch, John. "The War on Opioids is Saving Lives. But It's Also Killing People Like Me." March 27, 2019. https://www.washingtonpost.com/opinions/the-war-on-opioids-is-saving-lives-but-its-also-killing-people-like-me/2019/03/27/cead0a6f-50e2-11e9-a3f7-000119000000/	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
19081	Publicly Available	Højsted, Jette and Per Sjögren. "Addiction to opioids in chronic pain patients: a literature review." European Journal of Pain Vol. 11, No. 5 (2007): pp. 490-518.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
19082	Publicly Available	Intermountain Healthcare. "Management of Chronic Non-Cancer Pain." 2012. https://intermountainhealthcare.org/external/ncid=591023333 .	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
19083	Publicly Available	Kesselheim, Aaron S., et al. "A Randomized Study of How Physicians Interpret Research Funding Disclosures." New England Journal of Medicine Vol. 367, No. 12 (2012): pp. 1119-27.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
19084	Publicly Available	Kosten, Thomas R. and Tony P. George. "The neurobiology of opioid dependence: implications for treatment." <i>Science & Practice Perspectives</i> Vol. 1, No. 1 (2002): p. 13.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
19085	Publicly Available	Lacasse, Jeffrey R. and Jonathan Leo. "Knowledge of ghostwriting and financial conflicts-of-interest reduces the perceived credibility of biomedical research." <i>BMC Research Notes</i> Vol. 4, No. 27 (2011): pp. 1-6.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
19086	Publicly Available	Ling, Walter, Larissa Mooney, and Maureen Hillhouse. "Prescription opioid abuse, pain and addiction: clinical issues and implications." <i>Drug and Alcohol Review</i> Vol. 30, No. 3 (2011): pp. 300-05.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
19087	Publicly Available	Llorente, Elizabeth. "As doctors taper or end opioid prescriptions, many patients driven to despair, suicide." <i>December 10, 2018.</i> https://www.foxnews.com/health/as-opioids-become-taboo-doctors-taper-down-or-abandon-pain-patients-driving-many-to-suicide	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
19088	Publicly Available	Margarit Cesar, et al. "Breakthrough cancer pain—still a challenge." <i>Journal of Pain Research</i> Vol. 5 (2012): p. 559.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
19089	Publicly Available	Massachusetts Medical Society, "Opioid Therapy and Physician Communication Guidelines." 2015. http://www.massmed.org/Advocacy/Key-Issues/Opioid-Abuse/Opioid-Therapy-and-Physician-Communication-Guidelines-(pdf) .	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
19090	Publicly Available	Medical Board of California, "Guidelines for Prescribing Controlled Substances for Pain," 2014. http://www.mbc.ca.gov/licenses/prescribing/pain_guidelines.pdf	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
19091	Publicly Available	Medline Plus, "Opiate and Opioid Withdrawal." https://medlineplus.govency/article/000949.htm	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Tera exhibit because J&J and Janssen have not had the opportunity to review them)
19092	Publicly Available	Mercadante, Sebastiano, et al. "Factors influencing the use of opioids for breakthrough cancer pain: A secondary analysis of the TOPS-MS study." <i>European Journal of Pain</i> Vol. 23, No. 4 (2018): pp. 719-26.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
19093	Publicly Available	Mercadante, Sebastiano, et al. "Episodic (breakthrough) pain: consensus conference of an expert working group of the European Association for Palliative Care." <i>Cancer Vol. 94, No. 3</i> (2002): pp. 832-39.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
19094	Publicly Available	Minkowitz, Harold, et al. "Long-term safety of fentanyl sublingual spray in opioid-tolerant patients with breakthrough cancer pain." <i>Supportive Care in Cancer</i> Vol. 24, No. 6 (2016): pp. 2669-75.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
19095	Publicly Available	Mistry, Chetna J., et al. "Genetics of opioid dependence: a review of the genetic contribution to opioid dependence." <i>Current Psychiatry Reviews</i> Vol. 10, No. 2 (2014): pp. 156-67.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
19096	Publicly Available	Morasco, Benjamin J., et al. "Systematic review of prevalence, correlates, and treatment outcomes for chronic non-cancer pain in patients with comorbid substance use disorder." <i>Pain</i> Vol. 152, No. 3 (2011): pp. 488-97.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
19097	Publicly Available	Multiple Chronic Conditions Resource Center. "Chronic Pain Guidelines." https://www.multiplechronicconditions.org/chronic-pain-guidelines .	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
19098	Publicly Available	Munzing, Timothy. "Physician guide to appropriate opioid prescribing for noncancer pain." <i>The Permanente Journal</i> Vol. 21 (2017): pp. 160-69.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
19099	Publicly Available	Nalamachu, Srinivas, et al. "Long-term effectiveness and tolerability of sublingual fentanyl orally disintegrating tablet for the treatment of breakthrough cancer pain." <i>Current Medical Research and Opinion</i> Vol. 27, No. 3 (2011): pp. 519-30.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
19100	Publicly Available	National Institute on Drug Abuse, "Overdose Death Rates," January 2019. https://www.drugabuse.gov/related-topics/trends-statistics/overdose-death-rates .	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
19101	Publicly Available	National Institute on Drug Abuse, "Treating Opioid Use Disorder during Pregnancy," 2017. https://www.drugabuse.gov/publications/treating-opioid-use-disorder-during-pregnancy/creating-opioid-use-disorder-during-pregnancy .	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
19102	Publicly Available	NIH National Cancer Institute, "Fentanyl Citrate." https://www.cancer.gov/publications/dictionaries/cancer-drug/def/fentanyl-citrate	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
19103	Publicly Available	O'Donnell, Jane and Ken Allmucker. "Feds issue new warning to doctors: Don't skip too much on opioid pain pills." USA Today, April 24, 2019. https://www.usatoday.com/story/news/health/2019/04/24/opioid-pain-pills-crackdown-doctors-prescriptions-cdc-fda/3562373002/ .	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
19104	Publicly Available	Pasik, Steven D., Kenneth L. Kirsh, and Lynn Webster. "Pseudosaddiction revisited: a commentary on clinical and historical considerations." Pain Management Vol. 1, No. 3 (2011): pp. 239-48.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
19105	Publicly Available	Pasik, Steven D., et al. "Aberrant Drug-Related Behavior Observed During Clinical Studies Involving Patients Taking Chronic Opioid Therapy for Persistent Pain and Fentanyl Buccal Tablet for Breakthrough Pain." Journal of Pain and Symptom Management Vol. 41, No. 1 (2011): pp. 116-25.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
19106	Publicly Available	Payne, Richard. "Recognition and diagnosis of breakthrough pain." Pain Medicine Vol. 8, Supplement 1 (2007): pp. S3-S7.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
19107	Publicly Available	Pertigotzi Jr., Joseph V., Meredith Rosenblatt, D. J. Mariano, and J. Bisney. "Tapering opioid therapy: clinical strategies." Pain Management Vol. 8, No. 6 (Nov 1, 2018); pp. 409-13.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
19108	Publicly Available	Pertigotzi Jr., Joseph V., et al. "Going beyond prescription pain relievers to understand the opioid epidemic: the role of illicit fentanyl, new psychoactive substances, and street heroin." Postgraduate Medicine Vol. 130, No. 1 (2018); pp. 1-8.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
19109	Publicly Available	Pollock, Madelyn, Oralia V. Bazaldua, and Alison E. Dobbie. "Appropriate prescribing of medications: an eight-step approach." American Family Physician Vol. 75, No. 2 (2007); pp. 231-36.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
19110	Publicly Available	Portenoy, Russell K. "Opioid therapy for chronic nonmalignant pain: clinicians' perspective." The Journal of Law, Medicine & Ethics Vol. 24, No. 4 (1996); pp. 296-309.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
19111	Publicly Available	Portenoy, Russell K., et al. "Prevalence and characteristics of breakthrough pain in opioid-treated patients with chronic noncancer pain." The Journal of Pain Vol. 7, No. 8 (2006); pp. 583-91.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
19112	Publicly Available	Portenoy, Russell K., et al. "Breakthrough pain in community-dwelling patients with cancer pain and noncancer pain, part 1: prevalence and characteristics." Journal of Opioid Management Vol. 6, No. 2 (2010); pp. 97-108.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
19113	Publicly Available	Portenoy, Russell K. and Kathy M. Foley. "Chronic Use of Opioid Analgesics in Non-Malignant Pain: Report of 38 Cases." Pain Vol. 25 (1986); pp. 171-86.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
19114	Publicly Available	Radley, David C., Stan N. Finkelstein, and Randall S. Stafford. "Off-label prescribing among office-based physicians." Archives of Internal Medicine Vol. 166, No. 9 (2006); pp. 1021-26.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
19115	Publicly Available	Rappaport, Bob. "FDA Approval Letter for Fentora," September 25, 2006. https://www.accessdata.fda.gov/drugsatfda_docs/applletter/2006/021947s00001tr.pdf	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
19116	Publicly Available	Ray, James B. "Implications of the extended-release/long-acting opioid REMS for managed care." American Journal of Managed Care Vol. 21 (2015): pp. S177a-S87a	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
19117	Publicly Available	Robles, Frances. "Meth, the Forgotten Killer, Is Back. And It's Everywhere." The New York Times, February 13, 2018.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
19118	Publicly Available	Rosenberg, Mark. "Undertreated Pain Epidemic: Multi-Modality Approach to Pain Management." Journal of Managed Care Medicine Vol. 15, No. 1 (2012): pp. 30-37.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
19119	Publicly Available	Rosenblum, Andrew, et al. "Opioids and the treatment of chronic pain: controversies, current status, and future directions." Experimental and Clinical Psychopharmacology Vol. 16, No. 5 (2008): pp. 405-16.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
19120	Publicly Available	Rudowska, Joanna. "Management of breakthrough pain due to cancer." Contemporary Oncology Vol. 16, No. 6 (2012): pp. 498-501.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
19121	Publicly Available	Schuckit, Marc A. "Treatment of opioid-use disorders." New England Journal of Medicine Vol. 375, No. 4 (2016): pp. 357-68.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
19122	Publicly Available	Shimoyama, N., et al. "Efficacy and safety of sublingual fentanyl orally disintegrating tablet at doses determined from oral morphine rescue doses in the treatment of breakthrough cancer pain." Japanese Journal of Clinical Oncology Vol. 45, No. 2 (2014): pp. 189-96.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
19123	Publicly Available	Stimeone, Ronald. "Doctor Shopping Behavior and the Diversion of Prescription Opioids." Substance Abuse: Research and Treatment Vol. 11 (2017): pp. 1-10.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
19124	Publicly Available	Smith, Howard. "A comprehensive review of rapid-onset opioids for breakthrough pain." <i>CNS Drugs</i> Vol. 26, No. 6 (2012): pp. 509-35.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
19125	Publicly Available	Stanley, Theodore H. "The Fentanyl Story." <i>The Journal of Pain</i> Vol. 15, No. 12 (2014): pp. 1215-26.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.
19126	Publicly Available	Stobbe, Mike. "Today's Opioid Crisis Shares Chilling Similarities with Past Drug Epidemics." <i>The Chicago Tribune</i> , October 28, 2017.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.
19127	Publicly Available	Substance Abuse and Mental Health Services Administration (SAMHSA), "The CBHSQ Report: How People Obtain the Prescription Pain Relievers they Misuse," 2017. https://www.samhsa.gov/data/sites/default/files/report_2686/ShortReport-2686.html	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.
19128	Publicly Available	Substance Abuse and Mental Health Services Administration (SAMHSA), "Managing Chronic Pain in Adults With or in Recovery from Substance Use Disorders," 2012. https://store.samhsa.gov/system/files/sma13-4671.pdf .	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.
19129	Publicly Available	Substance Abuse and Mental Health Services Administration (SAMHSA), "Treatment Improvement Protocol 63," https://www.ncbi.nlm.nih.gov/books/NBK535268/pdf/5268/pdf/Bookshelf_NBK535268.pdf	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.
19130	Publicly Available	Sullivan, Jacob. "America's War on Pain Pills Is Killing Addicts and Leaving Patients in Agony." <i>Reason</i> , April 2018. https://reason.com/2018/03/08/americas-war-on-pain-pills-ist/	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.
19131	Publicly Available	Szalavitz, Mara. "When the Cure is Worse than the Disease." <i>The New York Times</i> , February 9, 2019. https://www.nytimes.com/2019/02/09/opinion/sunday/pain-opioids.html	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
19132	Publicly Available	Taylor, Donald R., et al. "Impact of breakthrough pain on quality of life in patients with chronic, noncancer pain: Patient perceptions and effect of treatment with oral transmucosal fentanyl citrate (OTFC®; ACTIQ®)." <i>Pain Medicine</i> Vol. 8, No. 3 (2007): pp. 281-88.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.
19133	Publicly Available	TIRF REMS Access, "An Overview for Prescribers," https://www.tirfremaccess.com/TirfU/remspdf/prescriber-overview.pdf	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
19134	Publicly Available	TIRF REMS Access, "Education Program for Prescribers and Pharmacists," https://www.tirfremaccess.com/TirfU/remspdf/education-and-ka.pdf	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
19135	Publicly Available	TIRF REMS Access, "Patient-Prescriber Agreement Form," https://www.tirfremaccess.com/TirfU/remspdf/ppat-form.pdf	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
19136	Publicly Available	TIRF REMS Access, "Prescriber Enrollment Form," https://www.tirfremaccess.com/TirfU/remspdf/prescriber-enrollment-form.pdf	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
19137	Publicly Available	Volkow, Nora D., and A. Thomas McLellan. "Opioid abuse in chronic pain—misconceptions and mitigation strategies." <i>New England Journal of Medicine</i> Vol. 374, No. 13 (2016): pp. 1253-63.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
19138	Publicly Available	Vowles, Kevin E., et al. "Rates of opioid misuse, abuse, and addiction in chronic pain: a systematic review and data synthesis." <i>Pain</i> Vol. 156, No. 4 (2015): pp. 569-76. https://www.wehnd.com/back-pain/guide/pain-specialists#2	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
19139	Publicly Available	WebMD, "8 Specialists Who Treat Pain," https://www.webmd.com/back-pain/guide/pain-specialists#2	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
19140	Publicly Available	Webster, Lynn R., et al. "Fentanyl buccal tablet compared with immediate-release oxycodone for the management of breakthrough pain in opioid-tolerant patients with chronic cancer and noncancer pain: a randomized, double-blind, crossover study followed by a 12-week open-label phase to evaluate patient outcomes." <i>Pain Medicine</i> Vol. 14, No. 9 (2013): pp. 1332-45.	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
19141	Publicly Available	Webster, Lynn R. and M. Beth Dove, "Optimizing Opioid Treatment for Breakthrough Pain." 2007. www.medscape.org/viewarticle/563417	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
19142	Publicly Available	Weissman, David E. and J. David Haddox. "Opioid pseudoaddiction—an iatrogenic syndrome." <i>Pain</i> Vol. 36, No. 3 (1989): pp. 363-66.	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
19143	Publicly Available	World Health Organization, "Guidelines for the Identification and Management of Substance Use and Substance Use Disorders in Pregnancy," 2014. https://www.who.int/substance_abuse/publications/pregnancy_guidelines/en/ .	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
19144	Publicly Available	TIRF REMS Access, "Education Program for Prescribers and Pharmacists," https://www.tirfremssaccess.com/TirfU/remss/pdff/education-and-ka.pdf .	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
19145	Publicly Available	TIRF REMS Access, "Patient-Prescriber Agreement Form."	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
19146	Publicly Available	https://www.tirfremssaccess.com/TirfU/remss/pdff/ppaf-form.pdf .	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
19147	Publicly Available	TIRF REMS Access, "Prescriber Enrollment Form."	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
19148	Publicly Available	https://www.tirfremssaccess.com/TirfU/remss/pdff/prescriber-enrollment-form.pdf .	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
19149	Publicly Available	Volkow, Nora D., and A. Thomas McLellan. "Opioid abuse in chronic pain—misconceptions and mitigation strategies." <i>New England Journal of Medicine</i> Vol. 374, No. 13 (2016): pp. 1253-63.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
19150	Publicly Available	Vowles, Kevin E., et al. "Rates of opioid misuse, abuse, and addiction in chronic pain: a systematic review and data synthesis." <i>Pain</i> Vol. 156, No. 4 (2015): pp. 569-76.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
19151	Publicly Available	WebMD. "8 Specialists Who Treat Pain." https://www.webmd.com/back-pain/guide/pain-specialists#2 , accessed April 26, 2019.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
19152	Publicly Available	Webster, Lynn R., et al. "Fentanyl buccal tablet compared with immediate-release oxycodone for the management of breakthrough pain in opioid-tolerant patients with chronic cancer and noncancer pain: a randomized, double-blind, crossover study followed by a 12-week open-label phase to evaluate patient outcomes." <i>Pain Medicine</i> Vol. 14, No. 9 (2013): pp. 1332-45.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
19153	Publicly Available	Webster, Lynn R. and M. Beth Dove. "Optimizing Opioid Treatment for Breakthrough Pain." 2007. www.medscape.org/viewarticle/563417 , accessed October 10, 2017.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
19154	Publicly Available	Weissman, David E. and J. David Haddox. "Opioid pseudotolerance—an iatrogenic syndrome." <i>Pain</i> Vol. 36, No. 3 (1989): pp. 363-66.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
19155	Publicly Available	World Health Organization. "Guidelines for the Identification and Management of Substance Use and Substance Use Disorders in Pregnancy." 2014. https://www.who.int/substance_abuse/publications/pregnancy_guidelines/en/ .	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
19156	Publicly Available	21 C.F.R. § 202.1	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Tera exhibit because J&J and Janssen have not had the opportunity to review them)
19157	Publicly Available	21 C.F.R. § 312.2	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
19158	Publicly Available	"Actiq Label, November 1998." 1998. https://www.accessdata.fda.gov/drugsatf_da_docs/label/1998/20747lbl.pdf .	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
19159	Publicly Available	"Fentora Label, September 2006." 2006. https://www.accessdata.fda.gov/drugsatf_da_docs/label/2006/021947lbl.pdf .	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
19160	Publicly Available	"Statement from FDA Commissioner Scott Gottlieb, M.D. on the agency's 2019 policy and regulatory agenda for continued action to forcefully address the tragic epidemic of opioid abuse." February 29, 2019. Available at https://www.fda.gov/news-events/press-announcements/statement-fda-commissioner-scott-gottlieb-md-agencys-2019-policy-and-regulatory-agenda .	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
19161	Publicly Available	Adeernathy, Amy P., Jane L. Wheeler, and Barry V. Fortner. "A Health Economic Model of Breakthrough Pain." American Journal of Managed Care Vol. 14, No. 5 (2008): pp. S129-S40.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
19162	Publicly Available	Akinboro, Oladimeji Akinola et al., "Opioid Use Is NOT Associated with in-Hospital Mortality Among Patients with Sickle CELL Disease in the United States: Findings from the National Inpatient Sample." Blood Vol. 132, Supplement 1: 315 (2018).	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
19163	Publicly Available	American Pain Foundation, "Treatment Options: A Guide for People Living with Pain."	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	Stare's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
19164	Publicly Available	Ashburn, Michael A., Kieran A. Stevin, John Messina, and Fang Xie. "The efficacy and safety of fentanyl buccal tablet compared with immediate-release oxycodone for the management of breakthrough pain in opioid-tolerant patients with chronic pain." <i>Anesthesia & Analgesia</i> Vol. 112, No. 3 (2011): pp. 693-702	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
19165	Publicly Available	Burton, Beth and Giovambattista Zepparella. "Assessing the impact of breakthrough cancer pain." <i>British Journal of Nursing</i> Vol. 20, Supplement 5 (2011): pp. S14-S19.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
19166	Publicly Available	Caraceni, Augusto, Andrew Davies, Philippe Pouliat, Hernán Cortés-Funes, Sunil J. Panchal, and Guido Fanelli. "Guidelines for the management of breakthrough pain in patients with cancer." <i>Journal of the National Comprehensive Cancer Network</i> Vol. 11, Supplement 1 (2013): pp. S-29-S-36.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
19167	Publicly Available	Chang, Andrew, Eric J. Roeland, Rabia S. Atayee, Carolyn Revya, and Joseph D. Ma. "Transmucosal immediate-release fentanyl for breakthrough cancer pain: opportunities and challenges for use in palliative care." <i>Journal of Pain & Palliative Care Pharmacotherapy</i> Vol. 29, No. 3 (2015): pp. 247-60.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
19168	Publicly Available	Chou, Roger, et al., "Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain." <i>The Journal of Pain</i> Vol. 10, No. 2 (2009): pp. 113-30.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
19169	Publicly Available	CMS. <i>Pharmacy Self-Auditing</i> . December 2015.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
19170	Publicly Available	Collett, B. J. "Chronic opioid therapy for non-cancer pain." <i>British Journal of Anaesthesia</i> Vol. 87, No. 1 (2001): pp. 133-43.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
19171	Publicly Available	Coluzzi, Paul H. et al., "Breakthrough cancer pain: a randomized trial comparing oral transmucosal fentanyl citrate (OTFC®) and morphine sulfate immediate release (MSIR®)." Pain Vol. 91(2001), pp. 123-30.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
19172	Publicly Available	Dahlhauer J. et al., "Prevalence of Chronic Pain and High-Impact Chronic Pain Among Adults — United States," 2016. Morbidity and Mortality Weekly Report (2018), 67:1001–1006. https://www.cdc.gov/mmwr/volumes/67/wr/mm6736a2.htm	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
19173	Publicly Available	FDA, Addendum to the FDA briefing information to summarize TIRF REMS issues relevant to the August 3, 2018 meeting, July 25, 2018.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
19174	Publicly Available	FDA, "Approved Risk Evaluation and Mitigation Strategies," September 7, 2017, https://www.accessdata.fda.gov/scripts/cder/remis/index.cfm?event=RemisDetails.page&R_EMS=60	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
19175	Publicly Available	FDA, "Development & Approval Process (Drugs)," https://www.fda.gov/Drugs/Development/ApprovalProcess/default.htm	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
19176	Publicly Available	FDA, "FDA's Role in Managing Medication Risks," https://www.fda.gov/Drugs/DrugsSafety/REMS/ucm592672.htm	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
19177	Publicly Available	FDA, "FDA Approved Drug Products, Fentora," https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.proc ess&Ap_dINo=021947	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
19178	Publicly Available	FDA, "Good Reprint Practices for the Distribution of Medical Journal Articles and Medical or Scientific Reference Publications on Unapproved New Uses of Approved Drugs and Approved or Cleared Medical Devices," January 13, 2009, https://www.fda.gov/regulatory-information/search-fda-guidance-documents/good-reprint-practices-distribution-medical-journal-articles-and-medical-or-scientific-reference-publications	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative; 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
19179	Publicly Available	FDA, Guidance for Industry, Development and Use of Risk Minimization Action Plans, March 2005, https://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidanc_071616.pdf .	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative; 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
19180	Publicly Available	FDA, "A Guide to Safe Use of Pain Medicine," https://www.fda.gov/ForConsumers/ConsumerUpdates/ucm095673.htm	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative; 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
19181	Publicly Available	FDA, An Introduction to the Improved FDA Prescription Drug Labeling, 2006.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative; 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
19182	Publicly Available	FDA, Managing the Risks From Medical Product Use Creating a Risk Management Framework, May 1999, https://hdl.handle.net/2027/umn.31951d016951490 .	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative; 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
19183	Publicly Available	FDA, Medical Product Communications That Are Consistent With the FDA-Required Labeling — Questions and Answers; Guidance for Industry, June 2018, https://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidanc_037130.pdf	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative; 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
19184	Publicly Available	FDA, "Off-Label and Investigational Use Of Marketed Drugs, Biologics, and Medical Devices - Information Sheet," July 12, 2018, http://www.fda.gov/RegulatoryInformation/Guidances/ucm126486.htm	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative; 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Rates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
19185	Publicly Available	FDA, "Standardizing and Evaluating Risk Evaluation and Mitigation Strategies," 2014.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
19186	Publicly Available	FDA, "Use of Approved Drugs for Unlabeled Indications," FDA Drug Bulletin Vol. 12, No. 1 (April, 1982).	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
19187	Publicly Available	FDA CDER, MAPP 6700.1: Risk Management Activities in OND and ODS, Manual of Policies and Procedures.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
19188	Publicly Available	Fine, Perry G., John Messina, Fang Xie, and James Rathmell, "Long-term safety and tolerability of fentanyl buccal tablet for the treatment of breakthrough pain in opioid-tolerant patients with chronic pain: an 18-month study," Journal of Pain and Symptom Management Vol. 40, No. 5 (2010); pp. 747-60.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
19189	Publicly Available	Fishbain, David A., Brandy Cole, John Lewis, Hubert L. Rosomoff, and R. Steele Rosomoff, "What percentage of chronic nonmalignant pain patients exposed to chronic opioid analgesic therapy develop abuse/addiction and/or aberrant drug-related behaviors? A structured evidence-based review," Pain Medicine Vol. 9, No. 4 (2007); pp. 444-59.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
19190	Publicly Available	Fishman, Scott M. Responsible Opioid Prescribing: A Physician's Guide. Washington, DC: Waterford Life Sciences, 2007.		
19191	Publicly Available	Forther, Barry V., Theodore A. Okon, and Russell K. Portenoy, "A survey of pain-related hospitalizations, emergency department visits, and physician office visits reported by cancer patients with and without history of breakthrough pain," The Journal of Pain Vol. 3, No. 1 (2002), pp. 38-44.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
19192	Publicly Available	Furlan, Andrea D., Juan A. Sandoval, Angela Mallis-Gagnon, and Eldon Tunks. "Opioids for chronic noncancer pain: a meta-analysis of effectiveness and side effects." <i>CMAJ</i> Vol. 174, No. 11 (2006), pp. 1589-94.	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402, Speculative, Cumulative, 12 O.S. § 2403, Confusion/prejudice, 12 O.S. § 2403.	
19193	Publicly Available	Gottlieb, Scott, Remarks by Dr. Gottlieb at the FDA Online Opioid Summit, June 27, 2018. https://www.fda.gov/NewsEvents/Speeches/ucm611945.htm .	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402, Speculative, Cumulative, 12 O.S. § 2403, Confusion/prejudice, 12 O.S. § 2403.	
19194	Publicly Available	Haythornthwaite, Jennifer A., Lynette A. Menefee, Amy L. Quatrano-Placentini, and Marco Pappagallo. "Outcome of Chronic Opioid Therapy for Non-Cancer Pain." <i>Journal of Pain and Symptom Management</i> Vol. 15, No. 3 (1998): pp. 185-94.	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402, Speculative, Cumulative, 12 O.S. § 2403, Confusion/prejudice, 12 O.S. § 2403.	
19195	Publicly Available	Jamison, Robert N., Edgar L. Ross, Edward Michna, Li Q. Chen, Caroline Holcomb, and Ajay D. Wasan. "Substance Misuse Treatment for High Risk Chronic Pain Patients on Opioid Therapy: A Randomized Trial." <i>Pain</i> Vol. 150, No. 3 (2010): pp. 390-400.	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402, Speculative, Cumulative, 12 O.S. § 2403, Confusion/prejudice, 12 O.S. § 2403.	
19196	Publicly Available	Jamison, Robert N., Juliana Serrallier, and Edward Michna. "Assessment and Treatment of Abuse Risk in Opioid Prescribing for Chronic Pain." <i>Pain Research and Treatment</i> Vol. 2011 (2011): pp. 1-12.	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402, Speculative, Cumulative, 12 O.S. § 2403, Confusion/prejudice, 12 O.S. § 2403.	
19197	Publicly Available	Kalso, Eija, Jayne E. Edwards, R. Andrew Moore, and Henry J. McQuay. "Opioids in chronic non-cancer pain: systematic review of efficacy and safety." <i>Pain</i> Vol. 112, No. 3 (2004): pp. 372-80.	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402, Speculative, Cumulative, 12 O.S. § 2403, Confusion/prejudice, 12 O.S. § 2403.	
19198	Publicly Available	Kesselheim, Aaron S., et al., "A Randomized Study of How Physicians Interpret Research Funding Disclosures." <i>New England Journal of Medicine</i> Vol. 367, No. 12 (2012): pp. 1119-27.	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402, Speculative, Cumulative, 12 O.S. § 2403, Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
19199	Publicly Available	Lacasse, Jeffrey R., and Jonathan Leo. "Knowledge of ghostwriting and financial conflicts-of-interest reduces the perceived credibility of biomedical research." <i>BMC Research Notes</i> Vol. 4, No. 27 (2011): pp. 1-6.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
19200	Publicly Available	Levy, Benjamin, Leonard Paulozzi, Karin A. Mack, and Christopher M. Jones. "Trends in Opioid Analgesic-Prescribing Rates by Specialty, U.S., 2007-2012." <i>American Journal of Preventive Medicine</i> Vol. 49, No. 3 (2015): pp. 409-13.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
19201	Publicly Available	Mercadante, Sebastiano, Claudio Adile, Francesco Masedu, Paolo Marchetti, Andrea Costanzi, and Federica Aielli. "Factors influencing the use of opioids for breakthrough cancer pain: A secondary analysis of the TOPS-MS study." <i>European Journal of Pain</i> Vol. 23, No. 4 (2018): pp. 719-26.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
19202	Publicly Available	Mercadante, Sebastiano et al., Steering Committee of the European Association for Palliative Care Research Network. "Episodic (breakthrough) pain: consensus conference of an expert working group of the European Association for Palliative Care." <i>Cancer</i> Vol. 94, No. 3 (2002): pp. 832-39.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
19203	Publicly Available	Minkowitz, Harold, Janet Bull, R. Charles Brownlow, Neha Parikh, and Richard Rauck. "Long-term safety of fentanyl sublingual spray in opioid-tolerant patients with breakthrough cancer pain." <i>Supportive Care in Cancer</i> Vol. 24, No. 6 (2016): pp. 2669-75.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
19204	Publicly Available	Nalamachu, Srinivas, et al., Prescription Pain Medication: Preserving Patient Access While Curbing Abuse, 2013.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
19205	Publicly Available	Nalamachu, Srinivas, David Hassman, Mark S Wallace, Sam Dumble, Rob Derrick, and Julian Howell. "Long-term effectiveness and tolerability of sublingual fentanyl orally disintegrating tablet for the treatment of breakthrough cancer pain." Current Medical Research and Opinion Vol. 27, No. 3 (2011): pp. 519-30	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
19206	Publicly Available	National Archives And Records Administration. (1972) Federal Register: 37 Fed. Reg. 16,503-16,504.	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
19207	Publicly Available	National Archives And Records Administration. (1975) Federal Register: 40 Fed. Reg. 15,392, 15,394.	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
19208	Publicly Available	National Archives And Records Administration. (1994) Federal Register: 59 Fed. Reg. 59,820, 59,821, 59,825.	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
19209	Publicly Available	National Archives And Records Administration. (1998) Federal Register: 63 Fed. Reg. 31,143, 31,153, 64,556, 64,579.	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
19210	Publicly Available	National Archives And Records Administration. (2003) Federal Register: 68 Fed. Reg. 6,062, 6,071.	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
19211	Publicly Available	Noble, Meredith et al., "Long-term opioid management for chronic noncancer pain." The Cochrane Database of Systematic Reviews Vol. 1 (2010): pp. 1-69.	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
19212	Publicly Available	Passik, S. D., and K. L. Kirsh. "Weighting in on the off-label use of Actiq for noncancer-related pain: a recipe for success or a recipe for disaster?" Pain Medicine Vol. 8, No. 2 (2007): pp. 130-3.	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
19213	Publicly Available	Passik, Steven D., John Messina, Anthony Golsorkhi, and Fang Xie. "Aberrant Drug-Related Behavior Observed During Clinical Studies Involving Patients Taking Chronic Opioid Therapy for Persistent Pain and Fentanyl Buccal Tablet for Breakthrough Pain." <i>Journal of Pain and Symptom Management</i> Vol. 41, No. 1 (2011): pp. 146-25.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
19214	Publicly Available	Payne, Richard. "Recognition and diagnosis of breakthrough pain." <i>Pain Medicine</i> Vol. 8, Supplement 1 (2007): pp. S3-S7.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
19215	Publicly Available	Portenoy, Russell K., Daniel S. Bennett, Richard Rauck, Steven Simon, Donald Taylor, Michael Brennan, and Steven Shoemaker. "Prevalence and characteristics of breakthrough pain in opioid-treated patients with chronic noncancer pain." <i>The Journal of Pain</i> Vol. 7, No. 8 (2006): pp. 583-91.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
19216	Publicly Available	Portenoy, Russell K., Daniel Bruns, Bonnie Shoemaker, and Steven A. Shoemaker. "Breakthrough pain in community-dwelling patients with cancer pain and noncancer pain, part 1: prevalence and characteristics." <i>Journal of Opioid Management</i> Vol. 6, No. 2 (2010): pp. 97-108.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
19217	Publicly Available	Rudowska, Joanna. "Management of breakthrough pain due to cancer." <i>Contemporary Oncology</i> Vol. 16, No. 6 (2012): pp. 498-501.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
19218	Publicly Available	Schuckit, Marc A. "Treatment of opioid-use disorders." <i>New England Journal of Medicine</i> Vol. 375, No. 4 (2016): pp. 357-68.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
19219	Publicly Available	Shimoyama, Naohito, et al., "Efficacy and safety of sublingual fentanyl orally disintegrating tablet at doses determined from oral morphine rescue doses in the treatment of breakthrough cancer pain," Japanese Journal of Clinical Oncology Vol. 45, No. 2 (2015): pp. 189-96.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
19220	Publicly Available	Simpson, Richard K., Evertson A. Edmondson, Charles F. Constant, and Connie Collier.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
19221	Publicly Available	"Transdermal fentanyl as treatment for chronic low back pain," Journal of Pain and Symptom Management Vol. 14, No. 4 (1997): pp. 218-24.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
19222	Publicly Available	Smith, Howard. "A comprehensive review of rapid-onset opioids for breakthrough pain," CNS Drugs Vol. 26, No. 6 (2012): pp. 509-35.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
19223	Publicly Available	Substance Abuse and Mental Health Services Administration (SAMHSA), "The CBHSQ Report: How People Obtain the Prescription Pain Relievers they Misuse," 2017. https://www.samhsa.gov/data/sites/default/files/report_20866/ShortReport-2686.html	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
19224	Publicly Available	Taylor, Donald R., Lynn R. Webster, Steven Y. Chun, Jeffrey Reinking, Mary Stegman, Steven Shoemaker, and Barry V. Fortner. "Impact of Breakthrough Pain on Quality of Life in Patients with Chronic, Noncancer Pain: Patient Perceptions and Effect of Treatment with Oral Transmucosal Fentanyl Citrate (OTFC, ACTIQ)," Pain Medicine Vol. 8, No. 3 (2007): pp. 281-88.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
19225	Publicly Available	TIRE REMS Access, "Education Program for Prescribers and Pharmacists," https://www.tifremaccess.com/TireU/rems/pdf/education-and-ka.pdf .	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
19226	Publicly Available	TIRF REMS Access, "Frequently Asked Questions," https://www.tirfremssaccess.com/TirfU/rems/pdf/faq.pdf	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402, Speculative, Cumulative, 12 O.S. § 2403, Confusion/prejudice, 12 O.S. § 2403.	
19227	Publicly Available	TIRF REMS Access, "Knowledge Assessment," https://www.tirfremssaccess.com/TirfU/rems/pdf/education-and-ka.pdf	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402, Speculative, Cumulative, 12 O.S. § 2403, Confusion/prejudice, 12 O.S. § 2403.	
19228	Publicly Available	TIRF REMS Access, "Patient-Prescriber Agreement Form," https://www.tirfremssaccess.com/TirfU/rems/pdf/ppaf-form.pdf	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402, Speculative, Cumulative, 12 O.S. § 2403, Confusion/prejudice, 12 O.S. § 2403.	
19229	Publicly Available	TIRF REMS Access, "Prescriber Enrollment Form," https://www.tirfremssaccess.com/TirfU/rems/pdf/prescriber-enrollment-form.pdf	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402, Speculative, Cumulative, 12 O.S. § 2403, Confusion/prejudice, 12 O.S. § 2403.	
19230	Publicly Available	U.S. Drug Enforcement Administration, "Practitioner's Manual - Section V - Valid Prescription Requirements," https://www.deadiversion.usdoj.gov/pub/s/manuals/pract/section5.htm	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402, Speculative, Cumulative, 12 O.S. § 2403, Confusion/prejudice, 12 O.S. § 2403.	
19231	Publicly Available	U.S. Drug Enforcement Agency, "Drug Scheduling," https://www.dea.gov/drug-scheduling .	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402, Speculative, Cumulative, 12 O.S. § 2403, Confusion/prejudice, 12 O.S. § 2403.	
19232	Publicly Available	Vowles, Kevin E., Mindy L. McEntee, Peter Szyahhan Julnes, Tessa Frohe, John P. Ney, and David N. van der Goes. "Rates of opioid misuse, abuse, and addiction in chronic pain: a systematic review and data synthesis." Pain Vol. 156, No. 4 (2015): pp. 569-76.	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402, Speculative, Cumulative, 12 O.S. § 2403, Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
19233	Publicly Available	Webster, Lynn R., Kieran A. Slevin, Arvind Narayana, Craig Q. Earl, and Ronghua Yang. "Fentanyl buccal tablet compared with immediate-release oxycodone for the management of breakthrough pain in opioid-tolerant patients with chronic cancer and noncancer pain: a randomized, double-blind, crossover study followed by a 12-week open-label phase to evaluate patient outcomes." <i>Pain Medicine</i> Vol. 14, No. 9, (2013): pp. 1332-45.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
19234	Publicly Available	Webster, Lynn R. and M. Beth Dove, "Optimizing Opioid Treatment for Breakthrough Pain," 2007. www.medscape.org/viewarticle/563417	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
20000	Publicly Available	Def Purdue Frederick First Set of Requests for Production of Docs from Pf	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
20001	Publicly Available	Def Purdue Frederick's Company's First Set of Interrogatories to Pf	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
20002	Publicly Available	Def Purdue Pharma, LP's First Set of Interrogatories to Pf	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
20003	Publicly Available	Def Purdue Pharma, LP's First Set of Requests for Production of Docs from Pf	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
20004	Publicly Available	Def Teva Pharmaceuticals USA Inc.'s First Set of Interrogatories to Pf	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
20005	Publicly Available	Def Teva Pharmaceuticals USA Inc.'s First Set of Requests for Production of Documents from Pf	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
20006	Publicly Available	Janssen Pharmaceuticals First Set of Rogs to Plaintiff	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
20007	Publicly Available	Teva Pharmaceuticals First Set of Interrogatories	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative; 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
20008	Publicly Available	Teva Pharmaceuticals First Set of Requests for Production	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative; 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
20009	Publicly Available	Cephalon's Second Set of Interrogatories to Plaintiff	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative; 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
20010	Publicly Available	Defendant Purdue Pharma Inc.'s First Set of Interrogatories to Plaintiff	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative; 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
20011	Publicly Available	Watson Lab First Interrogatories to Plaintiff	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative; 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
20012	Publicly Available	Watson Lab First Requests for Production to Plaintiff	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative; 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
20013	Publicly Available	Actavis First Interrogatories to Plaintiff	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative; 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
20014	Publicly Available	Actavis LLC First Requests for Production to Plaintiff	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative; 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
20015	Publicly Available	Actavis Pharma First Interrogatories to Plaintiff	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative; 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
20016	Publicly Available	Teva Second Interrogatories to Plaintiff	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative; 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
20017	Publicly Available	Actavis LLC First RFAs to Plaintiff	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative; 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
20018	Publicly Available	Actavis Pharma First RFAs to Plaintiff	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
20019	Publicly Available	Cephalon First RFAs to Plaintiff	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
20020	Publicly Available	Teva Pharmaceuticals USA First RFAs to Plaintiff	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
20021	Publicly Available	Watson Laboratories First RFAs to Plaintiff	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
20022	Publicly Available	Purdue Pharma LP's First Requests for Admission	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
20023	Publicly Available	Defendant Janssen's Second Set of Requests for Production of Documents from Plaintiff	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
20024	Publicly Available	Defendant Janssen's Second Set of Requests for Production of Documents	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
20025	Publicly Available	Defendant JJ's Second Set of Interrogatories to Plaintiff	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
20026	Publicly Available	Defendant JJ's 3rd Set of Interrogatories	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
20027	Publicly Available	Defendant JJ's 3rd Set of RFPs	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
20028	Publicly Available	Defendant Purdue Pharma Inc.'s First Requests for Admission to Plaintiff	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
20029	Publicly Available	Defendant Purdue Pharma Inc.'s First Requests for Production of Documents to Plaintiff	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
20030	Publicly Available	Defendant Purdue Pharma Inc.'s Second Set of Interrogatories to Plaintiff	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
20031	Publicly Available	Def Cephalon Inc.'s First Set of Interrogatories to Pf	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
20032	Publicly Available	Def Cephalon Inc.'s First Set of Requests for Production of Documents from Pf	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
20033	Publicly Available	Def Janssen Pharmaceuticals Inc.'s First Set of Requests for Production of Documents from Pf	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
20034	Publicly Available	Def Johnson and Johnson's First Set of Interrogatories to Pf	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
20035	Publicly Available	Def Johnson and Johnson's First Set of Requests for Production of Documents from Pf	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
20036	Publicly Available	Teva's RFAs to Plaintiff re Authenticity	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
20037	Publicly Available	State's Responses to Purdue Pharma Inc. First Set of Rogs	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
20038	Publicly Available	State's Responses and Objections to Watson Laboratories 1st INT	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
20039	Publicly Available	State's Responses and Objections to Watson Laboratories 1st RFP	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
20040	Publicly Available	State's Responses to Actavis LLC 1st INT	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402, Speculative, Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
20041	Publicly Available	State's Responses to Actavis LLC 1st RFP	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402, Speculative, Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
20042	Publicly Available	State's Responses to Actavis Pharma 1st INT	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402, Speculative, Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
20043	Publicly Available	State's Responses to Teva Pharmaceuticals USA 2nd INT	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402, Speculative, Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
20044	Publicly Available	State's Supp Responses to Cephalon 2nd Rogs	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402, Speculative, Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
20045	Publicly Available	State's Responses and Objections to JJ Third RFP	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402, Speculative, Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
20046	Publicly Available	State's Expert Disclosures	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402, Speculative, Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
20047	Publicly Available	Plaintiff's Responses and Objections to Janssen's First RFAs(final)	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402, Speculative, Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
20048	Publicly Available	Plaintiff's Responses and Objections to Janssen's Third Set of Interrogatories (final)	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402, Speculative, Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
20049	Publicly Available	Plaintiff's Responses and Objections to Actavis LLC's First RFAs	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402, Speculative, Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
20050	Publicly Available	Plaintiff's Responses and Objections to Actavis Pharma's First RFAs	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402, Speculative, Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
20051	Publicly Available	Plaintiff's Responses and Objections to Cephalon's First RFAs	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
20052	Publicly Available	Plaintiff's Responses and Objections to Teva's First RFAs	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
20053	Publicly Available	Plaintiff's Responses and Objections to Watson's First RFAs	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
20054	Publicly Available	State Responses to Purdue RFAs	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
20055	Publicly Available	Plaintiff's 1st Supp Responses and Objections to Actavis LLC's First RFAs	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
20056	Publicly Available	Plaintiff's 1st Supp Responses and Objections to Actavis Pharma's First RFAs	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
20057	Publicly Available	Plaintiff's 1st Supp Responses and Objections to Cephalon's First RFAs	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
20058	Publicly Available	Plaintiff's 1st Supp Responses and Objections to Janssen's First RFAs	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
20059	Publicly Available	Plaintiff's 1st Supp Responses and Objections to Teva's First RFAs	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
20060	Publicly Available	Plaintiff's 1st Supp Responses and Objections to Watson's First RFAs	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
20061	Publicly Available	State's Supplemental Responses to Purdue Pharma LP's RFAs	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
20062	Publicly Available	Plaintiff's Amended Disclosures	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
20063	Publicly Available	Plaintiff's 2d Supp Responses and Objections to Actavis Pharma's First RFAs (FINAL)	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
20064	Publicly Available	Plaintiff's 2d Supp Responses and Objections to Cephalon's First RFAs (FINAL)	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
20065	Publicly Available	Plaintiff's 2d Supp Responses and Objections to Watson's First RFAs (FINAL)	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
20066	Publicly Available	Plaintiff's 2nd Supp Responses and Objections to Actavis LLC's First RFAs (FINAL)	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
20067	Publicly Available	Plaintiff's 2nd Supp Responses and Objections to Janssen's First RFAs (FINAL)	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
20068	Publicly Available	Plaintiff's 2nd Supp Responses and Objections to Teva's First RFAs (FINAL)	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
20069	Publicly Available	Plaintiff's Responses and Objections to Janssen's Second Set of Requests for Production of Documents	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
20070	Publicly Available	Plaintiff's Responses and Objections to Johnson Johnson's Second Set of Interrogatories	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
20071	Publicly Available	Plaintiff's Responses and Objections to Johnson Johnson's Third Set of Interrogatories (FINAL)	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
20072	Publicly Available	Plaintiff's Responses and Objections to Johnson Johnson's Third Set of Requests for Production of Docs	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
20073	Publicly Available	State's Responses to Purdue Pharma Inc. Second Set of ROGS (final)	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
20074	Publicly Available	State's Responses to Purdue Pharma Inc.'s First Requests for Production (final)	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
20075	Publicly Available	State's Responses to Purdue Pharma Inc.'s First RFAs (final)	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
20076	Publicly Available	State's Initial Disclosures to Defs	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
20077	Publicly Available	The State of Oklahoma's Initial Disclosures to Def	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
20078	Publicly Available	Ps Resp and Obj to Janssen 1st RFP	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
20079	Publicly Available	Ps Resp and Obj to Purdue Pharma 1st RFP	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
20080	Publicly Available	Ps Resp and Obj to Purdue Frederick 1st RFP	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
20081	Publicly Available	Ps Resp and Obj to Cephalon 1st RFP	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
20082	Publicly Available	Ps Resp and Obj to Johnson and Johnson 1st RFP	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
20083	Publicly Available	Ps Resp and Obj to Teva 1st RFP	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
20084	Publicly Available	P ₈ Response and Objection to Purdue Pharma 1st INT	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
20085	Publicly Available	P ₈ Response and Objection to Teva 1st INT	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
20086	Publicly Available	P ₈ Response and Objection to Cephalon 1st INT	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
20087	Publicly Available	P ₈ Response and Objections to Janssen 1st INT	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
20088	Publicly Available	P ₈ Responses and Objections to Purdue Frederick 1st INT	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
20089	Publicly Available	P ₈ Responses and Objections to Johnson 1st INT	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
20090	Publicly Available	Plaintiff's Initial Disclosure of Individuals	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
20091	Publicly Available	Plaintiff's Initial Disclosures of Individuals	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
20092	Publicly Available	State's Responses to Cephalon Inc.'s Second Roggs	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
The Teva Defendants and Acquired Actavis Entities incorporate all other Teva and Actavis expert witness materials given to the State.				
The Teva Defendants and Acquired Actavis Entities incorporate all exhibits listed by Johnson & Johnson not otherwise captured on this list.				
The Teva Defendants and Acquired Actavis Entities incorporate all exhibits listed by the State not				

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
<p>The Teva Defendants and Acquired Actavis Entities incorporate all documents yet to be produced by The Teva Defendants and Acquired Actavis Entities incorporate all other exhibits used in State witness depositions not otherwise captured on this list.</p>				
<p>The Teva Defendants and Acquired Actavis Entities reserve the right to use any document or exhibit not included on this list for purposes of impeachment.</p>				